This report summarises the key issues impacting prices across a range of categories in the BioPharma industry in October-November 2024. Biologics contract manufacturing The BIOSECURE Act can lead to a supply shortage of biologic products, potentially driving prices upwards. The
Radiopharmaceuticals, a class of drugs that contain radioactive isotopes, are revolutionising the landscape of nuclear medicine, offering unprecedented opportunities for both diagnostic imaging and therapeutic applications. These sophisticated compounds are at the forefront of medical innovation, providing clinicians with powerful
This report summarises key supply chain events and their expected impact on life science prices over the period September-October 2024. Existing geopolitical tensions and fluctuating commodity stocks are expected to drive global market volatility and supply chain disruptions Contract Development
Antibody-Drug Conjugates (ADCs) – known as ‘the guided missiles of cancer therapy’ – are forecast to drive robust double-digit growth in contract development and manufacturing over the coming years, positioning them as a pivotal force in the biopharmaceutical landscape. ADCs
The high-growth India CDMO market is benefiting from this shifting geo-political tensions. We explore India’s impressive growth trajectory, which is forecast to see the CDMO market double over the next five years. Here is an overview of the market, with infographic and expert analysis.
This report summarises key macros events and their expected impact on life science prices over the period Jul-August 2024 Contract Development & Manufacturing The BIOSECURE Act, currently under consideration in the US Congress, is poised to significantly impact the biologics
In the biopharmaceutical industry, small molecule contract manufacturing plays a critical role in bringing new therapies to market. Small molecule drugs, characterised by their low molecular weight, are essential in treating a wide range of diseases due to their ability
In the rapidly evolving biopharmaceutical landscape, biologics or ‘large molecule’ therapies have emerged as a crucial segment, promising innovative treatments for a wide-range of diseases. 90% of biotechs choose to partner with a Contract Development and Manufacturing Organisation (CDMO) to
In the rapidly evolving field of biopharmaceutical research, Biobanks have emerged as a critical component in understanding and treating various diseases. We recently met Dr Tony Cox OBE, Chief Executive Officer of UK Biocentre to help explain the use of
The biologics market for inflammatory bowel disease (IBD) is rapidly evolving, with significant developments and increasing competition driving the field forward. June Seow, MPharm Senior Business Analyst for Lifescience Dynamics explains key trends shaping the market. Biologics Leading the Charge
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
